文献速递关节外科

全关节置换术围手术期抗生素预防:系统综述与Meta分析

Perioperative Antibiotic Prophylaxis in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Bone Joint Surg Am · 2019-01-01

该系统综述与Meta分析共纳入32项研究、51627例患者,比较单次术前抗生素与术前加术后继续使用以及≤24小时与>24小时预防的效应,总体合并效应分别为0.96(95%CI 0.73-1.26)和无差异,但证据GRADE质量低,作者认为需足效力的I级研究后再广泛实施缩短疗程。

要点

  • 单次术前剂量与继续术后用药的总体合并效应为0.96(95%CI 0.73-1.26),提示无差异。
  • 术后预防≤24小时与>24小时的总体合并效应显示无差异。
  • 所有纳入研究效力不足,且抗生素类型和疗程存在异质性。

核心结论

  • 本综述确认全关节置换术中手术抗生素预防的获益。
  • 现有证据未显示术后预防或超过24小时继续用药的额外获益。
  • 现有文献的总体GRADE证据质量低(偏倚风险高、发表偏倚风险高、精确度低)。
  • 本研究结果提示,在广泛实施缩短全关节置换术后手术抗生素预防疗程之前,需要足效力的I级研究评估其安全性及对SSI/PJI的影响。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Ovid MEDLINE和Ovid Embase,检索词为「surgical antimicrobial prophylaxis orthopedic」,遵循PRISMA指南,未限定发表时间范围。
  • 共筛选693项研究,评估32项研究。
  • 纳入23项随机对照试验、2项前瞻性队列研究、3项回顾性队列研究和4项病例对照研究,共51627例患者。
  • 提取抗生素类型、剂量数和疗程数据。

主要发现

  • 单次术前剂量与继续(术前加术后)给药的总体合并效应为0.96(95%CI 0.73-1.26),提示无差异。
  • 上述相对风险的95%CI可包括任一组约27%的降低。
  • 术后手术抗生素预防≤24小时与>24小时比较的总体合并效应显示无差异。
  • 所有纳入研究效力不足,且抗生素类型和疗程存在异质性。

关键数值与推荐

  • 单次术前剂量与继续给药比较的总体合并效应为0.96(95%CI 0.73-1.26)。
  • 术后手术抗生素预防≤24小时与>24小时比较的总体合并效应显示无差异。
  • 现有文献的总体GRADE证据质量低(偏倚风险高、发表偏倚风险高、精确度低)。
  • 证据等级为治疗性III级。

临床怎么用

  • 本综述确认全关节置换术中手术抗生素预防的获益。
  • 现有证据未显示术后手术抗生素预防或超过24小时继续用药的额外获益。
  • 作者认为需足效力的I级研究评估缩短手术抗生素预防疗程的安全性及对SSI/PJI的影响后再广泛实施。

局限性

  • 所有纳入研究效力不足,且抗生素类型和疗程存在异质性。
  • 现有文献的总体GRADE证据质量低(偏倚风险高、发表偏倚风险高、精确度低)。
  • 相对风险的95%CI可包括任一组约27%的降低。
  • 2017年美国CDC指南基于仅6项骨科研究,其中83%(5/6)发表于1987年至1991年。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2017 U.S. Centers for Disease Control and Prevention (CDC) guidelines for the prevention of surgical site infection (SSI) recommended against continuation of antibiotics postoperatively after total joint arthroplasty. This is disconcerting, as the revised guidelines are based on only 6 orthopaedic studies, of which 83% (5 of 6) were published from 1987 to 1991. The purpose of the current study was to conduct a systematic review and meta-analysis of the literature regarding the efficacy and duration of surgical antibiotic prophylaxis (SAP) in total joint arthroplasty. METHODS: PubMed, Ovid MEDLINE, and Ovid Embase were screened for "surgical antimicrobial prophylaxis orthopedic," in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, without a specified time frame with respect to publication date. A total of 693 studies were screened, and 32 studies were evaluated. Data were extracted regarding antibiotic type, number of doses, and duration. Prospective and retrospective studies examining perioperative antibiotics with subsequent SSI and periprosthetic joint infection (PJI) rates in total joint arthroplasty were included. RESULTS: Twenty-three randomized controlled trials (RCTs) and 2 prospective cohort, 3 retrospective cohort, and 4 case-control studies with a total of 51,627 patients were included in this review. The overall pooled effect for the comparison between a single preoperative dose of antibiotic and continued (preoperative plus postoperative) administration was 0.96 (95% confidence interval [CI], 0.73 to 1.26), suggesting no difference in effect. However, the 95% CI for the relative risk would include a reduction of approximately 27% in either group. The overall pooled effect from the comparison between SAP of ≤24 and >24 hours postoperatively demonstrated no difference in effect. All included studies were underpowered and heterogenous regarding type of antibiotic used and duration. CONCLUSIONS: Our review confirms the benefit of SAP utilization in total joint arthroplasty. The available evidence does not show added benefit of postoperative SAP or continuation beyond 24 hours. However, the overall GRADE (Grading of Recommendations Assessment, Development and Evaluation) of evidence of the available literature was low (high risk of bias, high risk of publication bias, and low precision). The findings of this study demonstrate the need for Level-I studies with adequate power to evaluate the safety of shortened SAP duration after total joint arthroplasty and its effect on SSI/PJI prior to widespread implementation. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Siddiqi A, Forte SA, Docter S, et al. Perioperative Antibiotic Prophylaxis in Total Joint Arthroplasty: A Systematic Review and Meta-Analysis. J Bone Joint Surg Am. 2019. PMID: 31045673. doi:10.2106/JBJS.18.00990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。